Re-Aim is a new early-stage pre-clinical company founded by Syncona, redefining how autoimmune diseases are treated by selectively depleting the pathogenic T cell subsets that drive chronic inflammation, autoimmunity and disease progression.

Founded: 2024
Founder: Asher Maroof PhD
Shareholding: 37.8%
Stage: Pre-clinical
Employees: 7
Seed financing: £7m

Unless stated all financials at 30 June 2026.

Re-Aim website

Re-Aim is a new early-stage pre-clinical company founded by Syncona during the year redefining how autoimmune diseases are treated by selectively depleting the pathogenic T cell subsets that drive chronic
inflammation, autoimmunity and disease progression.

Re-Aim aims to leverage its founder’s expertise alongside detailed analysis of patient samples to identify novel targets which define pathogenic subsets of Tcells in T-cell driven auto-immune diseases. The company plans to translate these findings over the coming year, nominating a development lead and moving towards an IND filing.

Syncona team

Roel Bulthuis

Roel Bulthuis is an Executive Partner of Syncona Investment Management Limited He brings more than 20 years of life science venture capital, business development and investment banking experience. In his role at Syncona, Roel supports the investment team and works with portfolio companies, drawing on his significant experience and network across the sector. He is a Board member of Anaveon, iOnctur…

View Roel's biography

Position

Board member

Qualification

MSc, MBA